secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001628280-26-016805
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances
--------------------------------------------------------------------------------

- Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.
- Cash, equivalents, and marketable securities $158.9M at Dec 31, 2025; extended runway into H1 2028 after $50M Jan 2026 financing.
- Ryan Maynard appointed CFO in Feb 2026, bringing over 25 years of biopharma finance experience.
- Lead candidate FHD-909 Phase 1 dose-escalation on track; collaboration with Lilly advancing.
- Selective CBP and EP300 degrader programs on track for IND-enabling studies in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026016805/0001628280-26-016805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026016805/fhtx-20260311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer